PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
EBIT growth above 1.5x TRAW's 100.00%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
39.05%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
24.67%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
25.26%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
25.26%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.67%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-25.67%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.29%
Negative 10Y OCF/share CAGR while TRAW stands at 77.68%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-10.29%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-46.03%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
68.39%
Net income/share CAGR at 50-75% of TRAW's 98.31%. Martin Whitman might question if the firm’s product or cost base lags behind.
68.39%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
65.23%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
-358.21%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-358.21%
Negative 5Y equity/share growth while TRAW is at 10162.80%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-14.02%
Negative 3Y equity/share growth while TRAW is at 7609.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.24%
We have a declining book value while TRAW shows 59775.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.21%
Debt growth of 8.21% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
We cut SG&A while TRAW invests at 61301.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.